Opendata, web and dolomites

VALID-SCREEN SIGNED

Validation of PreCursor-M for enhanced Cervical (Pre)Cancer detection

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

Project "VALID-SCREEN" data sheet

The following table provides information about the project.

Coordinator
SELF-SCREEN BV 

Organization address
address: BIOTHOF 15 1
city: AMSTERDAM
postcode: 1098 RX
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Netherlands [NL]
 Project website http://www.self-screen.nl/index.php
 Total cost 3˙264˙375 €
 EC max contribution 3˙264˙375 € (100%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SMEINST-2-2014
 Funding Scheme SME-2
 Starting year 2015
 Duration (year-month-day) from 2015-07-01   to  2019-03-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    SELF-SCREEN BV NL (AMSTERDAM) coordinator 3˙264˙375.00

Map

 Project objective

With an estimated 528,000 new cases and 266,000 deaths in 2012, cervical cancer (CC) is the fourth most common type of cancer in women, and the seventh overall. CC is preventable with regular screening tests and follow-up, and curable if found and treated early. In many countries, screening programmes for cervical cancer are in place, which have resulted in a marked decrease in cervical cancer incidence. hrHPV DNA testing will replace cytology as primary screening test for CC, but its drawback as stand-alone CC screening test is its low specificity, causing overdiagnosis and overtreatment. Triage of hrHPV women is essential to maintain a sustainable screening programme. PreCursor-M (Self-screen B.V.) is a proprietary molecular assay to determine disease progression and severity based on the methylation level of 3 host-biomarkers. Supplementing hrHPV DNA screening with PreCursor-M will provide information on the presence of infection, and the response by the host cells. This will allow identification of all women at risk for cervical cancer without overdiagnosis and overtreatment. The methylation level of three molecular markers (CADM1, MAL and miR124-2) was shown to increase proportional to cervical cancer progression and severity. In Precursor-M, these markers have been combined in a multiplex methylation marker panel. The markers have been separately validated in clinical settings, and the combined marker panel has been validated in laboratory and small-scale clinical settings. VALID-SCREEN will complete the final step towards commercial success for PreCursor-M: clinical validation of PreCursor-M in well-characterised cohorts, from five clinical centres, in four EU countries, as a triage test to hrHPV screening for cervical cancer.

 Deliverables

List of deliverables.
Communication plan Websites, patent fillings, videos etc. 2019-05-30 12:47:15
Data Managment PLan Websites, patent fillings, videos etc. 2019-05-30 11:25:30

Take a look to the deliverables list in detail:  detailed list of VALID-SCREEN deliverables.

 Publications

year authors and title journal last update
List of publications.
2018 Arno Floore, Albertus Hesselink, Anja Oštrbenk, Elia Alcaniz, Beate Rothe, Helle Pedersen, Montserrat Torres Hortal, Saskia Doorn, Wim Quint, Karl Ulrich Petry, Mario Poljak, Kate Cuschieri, Jesper Bonde, Silvia de Sanjosé, Maaike Bleeker, Daniëlle Heideman
Intra- and inter-laboratory agreement of the FAM19A4/mir124-2 methylation test: Results from an international study
published pages: e22854, ISSN: 0887-8013, DOI: 10.1002/jcla.22854
Journal of Clinical Laboratory Analysis 2019-04-13
2016 Roosmarijn Luttmer, Lise M. A. De Strooper, Renske D. M. Steenbergen, Johannes Berkhof, Peter J. F. Snijders, Daniëlle A. M. Heideman, Chris J. L. M. Meijer
Management of high-risk HPV-positive women for detection of cervical (pre)cancer
published pages: 1-14, ISSN: 1473-7159, DOI: 10.1080/14737159.2016.1217157
Expert Review of Molecular Diagnostics 2019-08-30

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "VALID-SCREEN" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "VALID-SCREEN" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

PanCareFollowUp (2019)

PanCareFollowUp: Novel, patient-centred survivorship care to improve care quality, effectiveness, cost-effectiveness and accessibility for survivors and caregivers

Read More  

GACD (2019)

Global Alliance for Chronic Diseases Secretariat

Read More  

AutoCRAT (2020)

Automated Cellular Robot-Assisted Technologies for translation of discovery-led research in Osteoarthritis

Read More